These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 26925240)
1. Albumin-based drug delivery: harnessing nature to cure disease. Larsen MT; Kuhlmann M; Hvam ML; Howard KA Mol Cell Ther; 2016; 4():3. PubMed ID: 26925240 [TBL] [Abstract][Full Text] [Related]
2. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement. Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735 [TBL] [Abstract][Full Text] [Related]
3. Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding. Schmøkel J; Voldum A; Tsakiridou G; Kuhlmann M; Cameron J; Sørensen ES; Wengel J; Howard KA Nanotechnology; 2017 May; 28(20):204004. PubMed ID: 28362634 [TBL] [Abstract][Full Text] [Related]
4. Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants. Petersen SS; Kläning E; Ebbesen MF; Andersen B; Cameron J; Sørensen ES; Howard KA Mol Pharm; 2016 Feb; 13(2):677-82. PubMed ID: 26654692 [TBL] [Abstract][Full Text] [Related]
5. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424 [TBL] [Abstract][Full Text] [Related]
6. Albumin-based drug designs for pharmacokinetic modulation. Pilati D; Howard KA Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):783-795. PubMed ID: 32729729 [TBL] [Abstract][Full Text] [Related]
7. An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications. Kuhlmann M; Hamming JBR; Voldum A; Tsakiridou G; Larsen MT; Schmøkel JS; Sohn E; Bienk K; Schaffert D; Sørensen ES; Wengel J; Dupont DM; Howard KA Mol Ther Nucleic Acids; 2017 Dec; 9():284-293. PubMed ID: 29246307 [TBL] [Abstract][Full Text] [Related]
8. Albumin and its application in drug delivery. Sleep D Expert Opin Drug Deliv; 2015 May; 12(5):793-812. PubMed ID: 25518870 [TBL] [Abstract][Full Text] [Related]
9. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein. Yang B; Kwon I Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743 [TBL] [Abstract][Full Text] [Related]
10. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT MAbs; 2021; 13(1):1893888. PubMed ID: 33691596 [TBL] [Abstract][Full Text] [Related]
11. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524 [TBL] [Abstract][Full Text] [Related]
12. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin. Yang B; Kim JC; Seong J; Tae G; Kwon I Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837 [TBL] [Abstract][Full Text] [Related]
13. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. Merten H; Brandl F; Zimmermann M; Schaefer JV; Irpinio L; Sand KMK; Nilsen J; Andersen JT; Zangemeister-Wittke U; Plückthun A Eur J Pharm Biopharm; 2021 Oct; 167():104-113. PubMed ID: 34303832 [TBL] [Abstract][Full Text] [Related]
14. A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation. Schelde KK; Nicholls K; Dagnæs-Hansen F; Bunting K; Rawsthorne H; Andersen B; Finnis CJA; Williamson M; Cameron J; Howard KA J Biol Chem; 2019 Mar; 294(10):3735-3743. PubMed ID: 30602565 [TBL] [Abstract][Full Text] [Related]
15. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. Rudnik-Jansen I; Howard KA J Control Release; 2021 Sep; 337():248-257. PubMed ID: 34245786 [TBL] [Abstract][Full Text] [Related]
16. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603 [TBL] [Abstract][Full Text] [Related]
17. Albumin as a versatile platform for drug half-life extension. Sleep D; Cameron J; Evans LR Biochim Biophys Acta; 2013 Dec; 1830(12):5526-34. PubMed ID: 23639804 [TBL] [Abstract][Full Text] [Related]
18. Albumin: the next-generation delivery technology. Howard KA Ther Deliv; 2015 Mar; 6(3):265-8. PubMed ID: 25853301 [No Abstract] [Full Text] [Related]
19. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies. Sand KM; Dalhus B; Christianson GJ; Bern M; Foss S; Cameron J; Sleep D; Bjørås M; Roopenian DC; Sandlie I; Andersen JT J Biol Chem; 2014 Jun; 289(24):17228-39. PubMed ID: 24764301 [TBL] [Abstract][Full Text] [Related]
20. The Minimal Effect of Linker Length for Fatty Acid Conjugation to a Small Protein on the Serum Half-Life Extension. Cho J; Park J; Tae G; Jin MS; Kwon I Biomedicines; 2020 Apr; 8(5):. PubMed ID: 32357510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]